Osimertinib + pemetrexed + carboplatin/cisplatin (FLAURA-2 regimen, EGFR-mut NSCLC, 1L)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-OSIMERTINIB DRUG-PEMETREXED DRUG-CARBOPLATIN DRUG-CISPLATIN |
|---|
| ID | REG-OSI-PEM-PLATINUM-NSCLC |
|---|---|
| Type | Regimen |
| Status | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-NSCLC-METASTATIC-2024 SRC-FLAURA-2-PLANCHARD-2023 SRC-NCCN-NSCLC-2025 |
Notes
FLAURA-2 (Planchard NEJM 2023, NCT04035486): osimertinib 80 mg PO daily + pemetrexed 500 mg/m² IV q3w + carboplatin AUC 5 OR cisplatin 75 mg/m² IV q3w × 4 cycles, then osi + pemetrexed maintenance until progression. Median PFS by investigator 25.5 vs 16.7 mo (HR 0.62; p<0.001) vs osi monotherapy; BICR PFS 29.4 vs 19.9 mo. CNS PFS HR 0.40 in patients with baseline CNS metastases. Higher Grade ≥3 AE rate (64% vs 27%) — additive cytopenia, mucositis, fatigue. Reserve for high-burden disease (CNS mets, L858R, large tumor volume) where PFS extension justifies added toxicity. FDA approval Feb 2024; NCCN cat 1 alternative-preferred 1L.
Used By
Indication
IND-NSCLC-EGFR-1L-OSI-CHEMO- IND-NSCLC-EGFR-1L-OSI-CHEMO